A statement released earlier today by Citigroup about Endo International PLC (NASDAQ:ENDP) bumps down the target price to $25.00
- Updated: September 16, 2016
Endo International PLC (NASDAQ:ENDP) had its estimated target price dropped to $25 by Citigroup in a report announced 9/16/2016. The target price indicates a potential upside of 0.22% based on the bussiness’ previous closing price.
Previously on 8/25/2016, Vetr Inc. released a statement for Endo International PLC(NASDAQ:ENDP) raised the target price from $0.00 to $21.95 that suggested an upside of 0.04%.
Displaying a price of $20.42, Endo International PLC (NASDAQ:ENDP) traded 0.19% higher on the day. The last stock close is down 9.08% relative to the 200-day average, compared to the Standard & Poor’s 500 Index which has fallen -0.01% over the same period. The company has been tracking to a 50-day average of $20.72 and 200-day average of $22.80. 933,850 shares of Endo International PLC were exchanged, down from ann average trading volume of 7,294,350
Recent Performance Chart:
With a total market value of $0.0, Endo International PLC has a one-year low of $12.56 and a 52 week high of $84.57 with a price-earnings ratio of 0.
A total of 19 brokers have released a research note on ENDP. Three analysts rate the company a strong buy, five analysts rate the company a buy, 13 analyts rate the stock a hold, 0 rate the stock to underperform, and lastly 0 firmsrate the company as sell with a one year target price of $30.05
General Company Details For Endo International PLC (NASDAQ:ENDP)
Endo International plc develops, manufactures, and distributes pharmaceutical products and devices worldwide. Its U.S. Branded Pharmaceuticals segment offers chronic pain management products, such as BELBUCA, OPANA ER, and Percocet; Lidoderm for opioid analgesics; and Voltaren gel for osteoarthritis pain, as well as XIAFLEX for treating PeyronieÂ’s and DupuytrenÂ’s contracture diseases. This segment also provides Supprelin LA for central precocious puberty treatment; testosterone replacement therapies, such as Aveed and TESTOPEL, as well as Fortesta and Testim gels; Frova and Sumavel DosePro for migraine headaches; Valstar, a sterile solution for intravesical instillation of valrubicin; and Vantas for the palliative treatment of prostate cancer. The companyÂ’s U.S. Generic Pharmaceuticals segment provides tablets, capsules, powders, injectables, liquids, nasal sprays, ophthalmics, and transdermal patches for pain management, urology, central nervous system disorders, immunosuppression, oncology, womenÂ’s health, and cardiovascular disease markets. Its International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas, including attention deficit hyperactivity disorder, pain, womenÂ’s health, and oncology; generic, branded generic, and over-the-counter products in the areas of dermatology and anti-infectives; injectables for the treatment of pain, anti-infectives, cardiovascular, and other therapeutics areas; and healthcare services, products, and solutions to hospitals, pharmacies, and practitioners, as well as for government healthcare programs. The company also provides Monarc subfascial hammock to treat female stress urinary incontinence; and Elevate transvaginal pelvic floor repair system for the treatment of pelvic organ prolapse. It sells its branded pharmaceuticals and generics directly, as well as through wholesale drug distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, and Ireland.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.